Pactamycin and sparsomycin, antitumor drugs which act synergistically with endotoxins, also potentiate the lethal toxicity of mice by Mycoplasma fermentans, strain K10. Sparsomycin (50 ug/20 g mouse, injected intraperitoneally 1 h after various doses of M. fermentans) exerted a minimal degree of synergism with few extra deaths, but with prolonged appearance of nonlethal disease. Pactamycin (75 gg in the same protocol) increased susceptibility to Mycoplasma-induced lethal toxicity approximately 1,000-fold. The optimal response was noted when pactamycin was administered in the period between 6 h before and 3 h after the administration of 108 colony-forming units of viable mycoplasmas. Doses of 12.5, 25, or 50 jig increased severity of signs, but only 75 ug/mouse produced synergism of the lethal effect. Methylprednisolone partially negated the synergism when injected simultaneously with the pactamycin 1 h after the cells. The lethal synergistic effect occurred with four species of Mycoplasma in addition to M. fermentans.
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Numerous antitumor compounds have been shown to exert synergistic toxicity with bacterial endotoxins in laboratory animals. Actinomycin D (1) was one of the first agents found to exhibit such activity, and the enhancement of lethality was so pronounced that it eventually became the basis for one type of endotoxin assay (9) . The current list of drugs with such synergistic potential ranges from daunomycin and nogalomycin to poly I: C and 6-mercaptopurine (7, 11, 12) . The classes represented include alkylating agents, folic acid antagonists, and nucleic acid inactivators, among others.
Recently, sparsomycin and pactamycin, both inhibitors of protein synthesis (2, 13) , have been reported to exert synergistic activity with gram-negative bacterial cells and products (2, 6, 13) . The effect has been studied in some detail, and it was established that the synergistic toxicity could be partially reduced with methylprednisolone (10) Animals. Three-to-four-week-old BALB mice (female, approximately 15 to 20 g each) were obtained from Charles River Breeding Laboratories, Wilmington, Mass. Animals were monitored daily for signs of lethal toxicity after being injected. These included roughened fur, huddling, anorexia, lethargy, diarrhea, and ocular exudates (3, 4) . Normal animals were scored (-), whereas those with some signs of disease were scored (+), and those displaying essentially all of the signs of the disease and in obvious distress were scored (+).
RESULTS
Pactamycin and sparsomycin were initially screened for their ability to none of the mice succumbed to lethal toxicity. Doses of 25 or 12.5 ug resulted in the appearance of signs of mild severity, and these animals also appeared to be normal after 24 h. No deaths were observed.
The synergistic toxicity of pactamycin and M. fermentans could be partially alleviated by methylprednisolone treatment. Table 4 (3, 4) . It includes some of the same biological responses observed in gram-negative endotoxemia. These include lethargy, diarrhea, ocular exudates, hepatocellular necrosis, shock lung, and potentiation by actinomycin D. This latter phenomenon prompted the present investigation which was designed to evaluate the synergistic potential of other antitumor drugs.
Sparsomycin and pactamycin inhibit protein synthesis and are known to potentiate the toxicity of endotoxins (6) . Our data indicate that they exert a similar effect with Mycoplasma cells. The activity of sparsomycin was minimal, whereas the synergistic activity of pactamycin was quite pronounced. Pactamycin (Tables 1 to 3) .
It was noted that the sparsomycin-treated mice occasionally displayed ocular hemorrhage, aOverall severity of disease and cumulative deaths by day 3; see Materials and Methods. 'MP, followed by K10 1 h later, followed by Pact 1 h later. c K10, followed 1 h later by Pact and MP given simultaneously. whereas the pactamycin-treated mice did not (Table 1) . This is consistent with the report of Karp and Bradley (6) , which indicated a high incidence of ocular hemorrhage in mice treated with multiple injections of sparsomycin and a much lower incidence in pactamycin-treated mice.
The potentiation of lethal toxicity by pactamycin could be partially blocked (Table 4) with methylprednisolone. Methylprednisolone is a steroid anti-inflammatory agent which can significantly prolong survival time in mice treated with pactamycin and bacterial endotoxin (10) . The sequence of injections was critical when protecting against Mycoplasmainduced lethal toxicity. Little effect was noted when methylprednisolone was administered before the organisms. This was most likely due to the fact that the Mycoplasma rapidly established foci of infection in the immunologically deficient mice, because little cellular resistance would be expected. In addition, the methylprednisolone may have all been bound to host cell target sites and unavailable for interaction with pactamycin 2 h later.
However, when the methylprednisolone and pactamycin were administered simultaneously 1 h after Mycoplasma injection a 50% sparing effect was noted. Apparently, the steroid can negate some activity of the pactamycin prior to its interaction with cells. Controls indicated that the sparing was not due to destruction of the M. fermentans K10 cells by methylprednisolone, so that the data indicate that the retardation of the synergistic toxicity probably resulted from an antibiotic-steroid interaction. Rose and Bradley (10) indicated that the antiendotoxin and anti-inflammatory properties are not necessarily related and that the diminution of synergistic toxicity is currently without an obvious mechanism of action.
The most curious aspect of this study was the synergistic toxicity of pactamycin and species of Mycoplasma unrelated to M. fermentans (Table 5 ). The toxicity of M. fermentans is known (3, 4) , and most other species, even in high doses, are not toxic for mice (8) . We confirmed this in our control series, but found marked toxicity in mice treated with pactamycin.
Numerous authors (7, 10, 12) have indicated that one must consider endotoxin-synergism in chemotherapy screening and treatment. It now appears that organisms besides gram-negative rods must also be considered in the design of therapeutic protocols. The precise nature of the mycoplasma-drug interaction is currently under investigation.
